{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T11:07:36Z","timestamp":1730200056487,"version":"3.28.0"},"reference-count":14,"publisher":"IEEE","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1109\/bibm.2018.8621427","type":"proceedings-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T19:49:10Z","timestamp":1550519350000},"page":"1653-1656","source":"Crossref","is-referenced-by-count":0,"title":["Comparing adverse effects of Hepatitis C drugs using FAERS data"],"prefix":"10.1109","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[]},{"given":"Xinyuan","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Jiayi","family":"Tong","sequence":"additional","affiliation":[]},{"given":"Jingcheng","family":"Du","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Jason H.","family":"Moore","sequence":"additional","affiliation":[]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Cui","family":"Tao","sequence":"additional","affiliation":[]}],"member":"263","reference":[{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw036"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360730"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.076646"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-010-0078-7"},{"journal-title":"FDA Copegus (ribavirin) tablets label","year":"0","key":"ref14"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-138"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0358-9"},{"journal-title":"FDA Questions and Answers on FDA’s Adverse Event Reporting System (FAERS)","year":"2016","key":"ref6"},{"key":"ref5","first-page":"57","article-title":"Phase IV of Drug Development","volume":"1","author":"suvarna","year":"2010","journal-title":"Perspectives Clinical Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.10453"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40264-013-0116-9","article-title":"Profiling Cumulative Proportional ReportingRatios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database","volume":"36","author":"allen","year":"2013","journal-title":"Drug Safety"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2014.04.008"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26"}],"event":{"name":"2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)","start":{"date-parts":[[2018,12,3]]},"location":"Madrid, Spain","end":{"date-parts":[[2018,12,6]]}},"container-title":["2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)"],"original-title":[],"link":[{"URL":"http:\/\/xplorestaging.ieee.org\/ielx7\/8609864\/8621069\/08621427.pdf?arnumber=8621427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T19:06:20Z","timestamp":1598209580000},"score":1,"resource":{"primary":{"URL":"https:\/\/ieeexplore.ieee.org\/document\/8621427\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1109\/bibm.2018.8621427","relation":{},"subject":[],"published":{"date-parts":[[2018,12]]}}}